Greenville Pathology, PA Adds Cervista HPV Test
http://www.pcwomensjournal.com/articles/122/1/Greenville-Pathology-PA-Adds-Cervista-HPV-Test/Page1.html
Beth Phillips-Ferrell
A Cytotechnologist by trade, I am the Practice Administrator for Greenville Pathology, PA. Greenville Pathology, PA is a privately-owned pathology laboratory specializing in surgical pathology, cytopathology, and molecular pathology. I did my undergraduate studies at the UNC-Wilmington; my professional studies and certification in cytology at Bexar County Hospital School of Cytotechnology in San Antonio, TX; and went back to school for my business degree at ECU. By Beth Phillips-Ferrell
Published on 02/2/2010
Greenville Pathology, PA, is pleased to announce the addition of Cervista to screen for the presence of high-risk types of human papilloma virus, which is strongly associated with the development of cervical cancer. Cervista HPV HR, approved by the FDA in March 2009, is the first new screening test for high-risk HPV in more than a decade.
Greenville Pathology, PA, is pleased to announce the addition of Cervista to screen for the presence of high-risk types of human papilloma virus, which is strongly associated with the development of cervical cancer. Cervista HPV HR, approved by the FDA in March 2009, is the first new screening test for high-risk HPV in more than a decade.
In the United States, about 10,000 women are diagnosed with cervical cancer each year, while about 3,700 die from the disease, according to the National Cancer Coalition (NCC), a patient advocacy group, making it the seventh leading cause of cancer death nationally. “Since there is such a strong correlation between this sexually transmitted virus known as the human papilloma virus (HPV)and cervical cancer, we felt compelled to stay abreast of the newest technology and to offer it to our clients and their patients” states Beth Phillips-Ferrell, practice administrator.
Greenville Pathology, PA offers the only fully FDA approved methodology for screening for cervical cancer in all types of patients: that is, (1) Cytyc ThinPrep Pap smear(2) Cytyc Imaged Pap smear and (3) Cervista HPV HR screening for human papilloma virus. Other technologies are FDA approved for portions of their product or for certain non-high risk populations; however, the above combination is approved for all patients. Greenville Pathology is proud to be the only local provider of this technology combination in Pitt County and the region.
If you would like to locate an office that utilizes this technology, please call the laboratory and ask for Beth Phillips-Ferrell at 561-7992 ext 236 or 888-708-7284.
In the United States, about 10,000 women are diagnosed with cervical cancer each year, while about 3,700 die from the disease, according to the National Cancer Coalition (NCC), a patient advocacy group, making it the seventh leading cause of cancer death nationally. “Since there is such a strong correlation between this sexually transmitted virus known as the human papilloma virus (HPV)and cervical cancer, we felt compelled to stay abreast of the newest technology and to offer it to our clients and their patients” states Beth Phillips-Ferrell, practice administrator.
Greenville Pathology, PA offers the only fully FDA approved methodology for screening for cervical cancer in all types of patients: that is, (1) Cytyc ThinPrep Pap smear(2) Cytyc Imaged Pap smear and (3) Cervista HPV HR screening for human papilloma virus. Other technologies are FDA approved for portions of their product or for certain non-high risk populations; however, the above combination is approved for all patients. Greenville Pathology is proud to be the only local provider of this technology combination in Pitt County and the region.
If you would like to locate an office that utilizes this technology, please call the laboratory and ask for Beth Phillips-Ferrell at 561-7992 ext 236 or 888-708-7284.